Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging

Perrot, Thomas Benoît De; Rager, Olivier; Scheffler, Max; Lord, Martin; Pusztaszeri, Marc; Iselin, Christophe; Ratib, Osman; Vallée, Jean‐Paul

doi:10.1007/s00259-014-2786-7

Cited by 46 publications

(37 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Correlation with anatomic images is essential for diagnosis. aging (eg, heterogeneous signal intensity on T2-weighted images, presence of a capsule) (9) (Fig 3). 18 F-Choline PET/CT and MR imaging can be used for staging of newly diagnosed prostate cancer (Fig 4).…”

Section: Teaching Pointsmentioning

confidence: 99%

Molecular Imaging of Prostate Cancer

Wibmer¹,

Burger²,

Sala³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

Prostate cancer is the most common noncutaneous malignancy among men in the Western world. The natural history and clinical course of prostate cancer are markedly diverse, ranging from small indolent intraprostatic lesions to highly aggressive disseminated disease. An understanding of this biologic heterogeneity is considered a necessary requisite in the quest for the adoption of precise and personalized management strategies. Molecular imaging offers the potential for noninvasive assessment of the biologic interactions underpinning prostate carcinogenesis. Currently, numerous molecular imaging probes are in clinical use or undergoing preclinical or clinical evaluation. These probes can be divided into those that image increased cell metabolism, those that target prostate cancer-specific membrane proteins and receptor molecules, and those that bind to the bone matrix adjacent to metastases to bone. The increased metabolism and vascular changes in prostate cancer cells can be evaluated with radiolabeled analogs of choline, acetate, glucose, amino acids, and nucleotides. The androgen receptor, prostate-specific membrane antigen, and gastrin-releasing peptide receptor (ie, bombesin) are overexpressed in prostate cancer and can be targeted by specific radiolabeled imaging probes. Because metastatic prostate cancer cells induce osteoblastic signaling pathways of adjacent bone tissue, bone-seeking radiotracers are sensitive tools for the detection of metastases to bone. Knowledge about the underlying biologic processes responsible for the phenotypes associated with the different stages of prostate cancer allows an appropriate choice of methods and helps avoid pitfalls. F-16b-fluoro5a-dihydrotestosterone, PSA = prostate-specific antigen, PSMA = prostate-specific membrane antigen

show abstract

Section: Teaching Pointsmentioning

confidence: 99%

Molecular Imaging of Prostate Cancer

Wibmer¹,

Burger²,

Sala³

et al. 2016

RadioGraphics

View full text Add to dashboard Cite

show abstract

“…6 Considering the present literature and the examples presented by Maurer et al, prostate cancer imaging with…”

Section: Conflict Of Interestmentioning

confidence: 80%

“…3 Together with the novel development of combined PET/MRI, the combination of excellent morphological detail, multiparametric functional information, and molecular PET data might lead to a significant improvement in detection and staging of PCa, and thus could help to optimize oncological treatment. [4][5][6] Here, based on our first clinical results, we describe 68 Ga-PSMA-L PET/MRI as a novel imaging technique for patients with PCa at different disease stages, and discuss potential future applications.…”

mentioning

confidence: 99%

Positron emission tomography/magnetic resonance imaging with ⁶⁸Gallium‐labeled ligand of prostate‐specific membrane antigen: Promising novel option in prostate cancer imaging?

et al. 2014

View full text Add to dashboard Cite

68Galliumlabeled ligand of prostate-specific membrane antigen ADC = apparent diffusion coefficient BS = bone scintigraphy CT = computed tomography DCE = dynamic contrast-enhanced Gs = Gleason score iAUC60 = initial area under the time-intensive curve (within 60 s) LN = lymph node(s) MBq = megabequerel MRI = magnetic resonance imaging PCa = prostate cancer PET = positron emission tomography PSMA = prostate-specific membrane antigen Ga-PSMA-L has been introduced in PET imaging of PCa with first promising results.2 As a result of relatively exclusive expression of PSMA in prostatic tissue, as well as increased expression in PCa, 68 Ga-PSMA-L was reported to show a favorable lesion-to-background ratio compared with the presently used choline-based PET examinations.3 Together with the novel development of combined PET/MRI, the combination of excellent morphological detail, multiparametric functional information, and molecular PET data might lead to a significant improvement in detection and staging of PCa, and thus could help to optimize oncological treatment. [4][5][6] Here, based on our first clinical results, we describe 68Ga-PSMA-L PET/MRI as a novel imaging technique for patients with PCa at different disease stages, and discuss potential future applications.Briefly, PET/MRI was carried out on a fully integrated whole-body hybrid PET/MRI system (Siemens Biograph mMR; Siemens Healthcare, Erlangen, Germany). After intravenous injection of 122 ± 17 MBq 68 Ga-PSMA-L, a diagnostic PET-examination of the trunk (from base of skull to the proximal femur) with simultaneous acquisition of coronal T1-weighted and fat saturated axial T2-weighted images was carried out followed by a diagnostic multiparametric MR examination of the pelvis including a 15-min PET scan (mean time from injection to imaging: 51 min, range 45-63 min). To prevent extinction artifacts as a result of urinary excretion of the tracer, furosemide was applied and the bladder was emptied before the start of the examination.Case 1: A 72-year-old patient without evidence of malignancy in two prior biopsies, but highly suspected PCa (PSA 13.9 ng/mL, free-to-total ratio 6.9%, digital rectal examination normal) underwent 68 Ga-PSMA-L PET/MRI and confirmation of a Gs 7b (4 + 3) PCa within the suspicious area on target biopsies without malignancy in the remaining biopsy cores (Fig. 1a-d).Case 2: A 72-year-old patient with biopsy-proven high-risk PCa was subjected to 68 Ga-PSMA-L PET/MRI showing local tumor, but no evidence of metastatic disease (Fig. 1e,f). Postoperative histological analysis after radical prostatectomy showed a poorly differentiated PCa Gs 8 (4 + 4) of the left prostatic lobe with extracapsular extension without evidence of metastatic LN (pT3a pN0 [0/29] cM0 L0 V0 Pn1 G3 R0).Case 3: A 74-year-old patient with locally advanced high-risk PCa (PSA 12.9 ng/mL; Gs 9 [4 + 5]; cT3) and suspicion of pelvine LN metastases on CT, but negative results in bone scintigraphy (Fig. 1g) underwent further staging with 68

show abstract

“…Transrektal ya da perineal biyopsiler suboptimal tanısal doğruluk göstermektedir; bu nedenle de metabolik-fonksiyonel görüntüleme kılavuzluğunda biyopsilere ihtiyaç vardır. Yapılan çeşitli çalışmalar, F-18 fluorokolin PET/MR'ın özellikle periferal zonda yerleşimli primer tümör odaklarının saptanmasında tek başına MR görüntülemeye üstün olduğunu göstermektedir (128,129,130). Ga-68 PSMA-HEBD-CC görüntülemesinin de prostat bezinde aktif primer tümör odaklarının saptanmasında üstün olduğu belirtilmektedir (126).…”

Section: Prostatkanserindepet/mrunclassified

Positron Emission Tomography/Magnetic Resonance Imaging Practices in Oncological Imaging

Aydos¹,

Akdemir²,

Atay³

2017

Nts

View full text Add to dashboard Cite

Tıbbi onkolojide tanı, evreleme, biyopsi yerinin saptanması, prognostik değerlendirme, tedavi planı seçimi, tedaviye yanıtın değerlendirilmesi, rekürren hastalık saptanması gibi durumlarda görüntüleme yöntemleri gittikçe artan bir yere sahiptir. Moleküler görüntüleme verileri ile anatomik görüntüleme verilerini bir araya getiren hibrit görüntüleme tekniklerinin üçüncü aşaması olan pozitron emisyon tomografisi/ manyetik rezonans (PET/MR) görüntüleme yöntemi, MR görüntülemenin yüksek rezolüsyonlu anatomik görüntülerini, fonksiyonel görüntüleme verilerini, florodeoksiglukoz (FDG) ve FDG dışı ajanlarla yapılan PET görüntülemenin sağladığı moleküler bilgileri birleştirerek primer tümör evrelemesi, tedavi yanıtının değerlendirilmesi, hastalık rekürrensinin saptanmasında yüksek tanısal doğruluk potansiyeline sahiptir. Bunlara ek olarak, PET ve MR görüntülemenin eş zamanlı olarak yapılabilmesi görüntüleme sürelerinin kısaltılmasında, hareket artefaktlarının düzeltilmesinde yararlı olabileceği gibi, tekrarlayan görüntüleme gerektiren hastalarda PET/ MR görüntüleme PET/BT'ye göre iyonize radyasyon dozunun azaltılmasında da etkilidir. MR görüntülemenin yüksek yumuşak doku kontrastı nedeniyle beyin tümörlerinde, baş-boyun tümörlerinde, yeni tanı meme kanserlerinde, yeni tanı akciğer kanserlerinde beyin metastazı varlığının araştırılmasında, abdominopelvik tümörlerde, hematolojik malignitelerde intramedüller alanın değerlendirilmesinde PET/MR görüntüleme PET/BT'ye tercih edilebilir ya da bölgesel görüntüleme şeklinde tamamlayıcı nitelikte kullanılabilir. PET/ BT ise MR görüntülemenin kontrendike olduğu durumlarda primer tümör evrelemesinde ve özellikle nodüler akciğer

show abstract

Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging

Cited by 46 publications

References 46 publications

Molecular Imaging of Prostate Cancer

Molecular Imaging of Prostate Cancer

Positron emission tomography/magnetic resonance imaging with ⁶⁸Gallium‐labeled ligand of prostate‐specific membrane antigen: Promising novel option in prostate cancer imaging?

Positron Emission Tomography/Magnetic Resonance Imaging Practices in Oncological Imaging

Contact Info

Product

Resources

About

Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging

Cited by 46 publications

References 46 publications

Molecular Imaging of Prostate Cancer

Molecular Imaging of Prostate Cancer

Positron emission tomography/magnetic resonance imaging with 68Gallium‐labeled ligand of prostate‐specific membrane antigen: Promising novel option in prostate cancer imaging?

Positron Emission Tomography/Magnetic Resonance Imaging Practices in Oncological Imaging

Contact Info

Product

Resources

About

Positron emission tomography/magnetic resonance imaging with ⁶⁸Gallium‐labeled ligand of prostate‐specific membrane antigen: Promising novel option in prostate cancer imaging?